Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus ...

Breakthroughs in tricuspid and mitral valve repair signal progress in heart treatment. BEIJING, June 3, 2025 /PRNewswire/ -- ...

Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of TRINITY Trial of LuX-Valve Plus, a ...

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

Progress with transcatheter tricuspid valve replacement (TTVR) candidate devices Topaz, LuX-Valve Plus, VDyne, and Trisol for ...

“Patients with ATTR-CM have progressive amyloid accumulation in the heart, which when untreated manifests as progressive heart failure, arrhythmias ... baseline New York Heart Association (NYHA) ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

restrictive fluid restriction impacts health status for patients with chronic heart failure found no added ... Overall, 504 adults diagnosed with NYHA class II/III HF at least 6 months before ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for finerenone for the treatment of adult patients with heart failure (HF ...

This analysis excluded participants with NYHA 4, or heart failure stage four because no ... patients felt better and had improved functional class.” This study did have some limitations, some ...

LV mass decreased by 11 g (0.4 oz), and cardiac adipose tissue dropped by 45 mL (1.5 fl oz). They concluded that these reductions may have contributed to the reduction in heart failure events seen ...